

## Product datasheet for **TL312343V**

### **p21 Ras (HRAS) Human shRNA Lentiviral Particle (Locus ID 3265)**

#### **Product data:**

<b>Product Type:</b>	shRNA Lentiviral Particles
<b>Product Name:</b>	p21 Ras (HRAS) Human shRNA Lentiviral Particle (Locus ID 3265)
<b>Locus ID:</b>	3265
<b>Synonyms:</b>	C-BAS/HAS; C-H-RAS; C-HA-RAS1; CTLO; H-RASIDX; HAMS; HRAS1; p21ras; RASH1
<b>Vector:</b>	pGFP-C-shLenti (TR30023)
<b>Format:</b>	Lentiviral particles
<b>Components:</b>	HRAS - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
<b>RefSeq:</b>	<a href="#">BC006499</a> , <a href="#">NM_001130442</a> , <a href="#">NM_001318054</a> , <a href="#">NM_005343</a> , <a href="#">NM_176795</a> , <a href="#">NM_176795.1</a> , <a href="#">NM_176795.2</a> , <a href="#">NM_176795.3</a> , <a href="#">NM_176795.4</a> , <a href="#">NM_005343.1</a> , <a href="#">NM_005343.2</a> , <a href="#">NM_005343.3</a> , <a href="#">NM_001130442.1</a> , <a href="#">NM_001130442.2</a> , <a href="#">BC006499.2</a> , <a href="#">BC095471</a> , <a href="#">BM801600</a> , <a href="#">BM801632</a> , <a href="#">BM808879</a> , <a href="#">NM_005343.4</a>
<b>UniProt ID:</b>	<a href="#">P01112</a>
<b>Summary:</b>	This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, cognitive disability, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene. [provided by RefSeq, Jul 2008]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).